Daniel E Speiser

Summary

Affiliation: Centre Hospitalier Universitaire Vaudois
Country: Switzerland

Publications

  1. ncbi Differentiation associated regulation of microRNA expression in vivo in human CD8+ T cell subsets
    Bruno Salaun
    Division of Clinical Onco Immunology, Ludwig Center for Cancer Research of the University of Lausanne, Switzerland
    J Transl Med 9:44. 2011
  2. ncbi Disease-driven T cell activation predicts immune responses to vaccination against melanoma
    Daniel E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital CHUV, Lausanne, Switzerland
    Cancer Immun 3:12. 2003
  3. ncbi Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells
    Daniel E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Hopital Orthopedique, Centre Hospitalier Universitaire Vaudois, Niveau 5, Aile Est, Av Pierre Decker 4, CH 1005 Lausanne, Switzerland
    Semin Cancer Biol 13:461-72. 2003
  4. ncbi Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring
    Daniel E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Immunother 27:298-308. 2004
  5. ncbi Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909
    Daniel E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Clin Invest 115:739-46. 2005
  6. ncbi In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells
    Daniel E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University Hospital CHUV, Lausanne, Switzerland
    Eur J Immunol 32:731-41. 2002
  7. ncbi Toward improved immunocompetence of adoptively transferred CD8+ T cells
    Daniel E Speiser
    Ludwig Institute for Cancer Research, Division of Clinical Onco Immunology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Clin Invest 115:1467-9. 2005
  8. ncbi The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cells
    D E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Immunol 167:6165-70. 2001
  9. ncbi Can hTERT peptide (540-548) -specific CD8 T cells recognize and kill tumor cells?
    Daniel E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland
    Cancer Immun 2:14. 2002
  10. ncbi Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes
    Daniel E Speiser
    Ludwig Center for Cancer Research, University of Lausanne, Lausanne CH 1011, Switzerland
    Proc Natl Acad Sci U S A 108:15318-23. 2011

Collaborators

Detail Information

Publications81

  1. ncbi Differentiation associated regulation of microRNA expression in vivo in human CD8+ T cell subsets
    Bruno Salaun
    Division of Clinical Onco Immunology, Ludwig Center for Cancer Research of the University of Lausanne, Switzerland
    J Transl Med 9:44. 2011
    ..MicroRNAs have been recently shown to play a key role in the regulation of haematopoiesis in mouse, but their implication in peripheral lymphocyte differentiation in humans remains largely unknown...
  2. ncbi Disease-driven T cell activation predicts immune responses to vaccination against melanoma
    Daniel E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital CHUV, Lausanne, Switzerland
    Cancer Immun 3:12. 2003
    ..Thus, peptide vaccines can efficiently boost CD8 T cells that are pre-activated by endogenous tumor antigen. Our results identify a new state of T cell responsiveness and help to explain and predict tumor vaccine efficacy...
  3. ncbi Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells
    Daniel E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Hopital Orthopedique, Centre Hospitalier Universitaire Vaudois, Niveau 5, Aile Est, Av Pierre Decker 4, CH 1005 Lausanne, Switzerland
    Semin Cancer Biol 13:461-72. 2003
    ..Careful immunogenicity comparison of vaccine formulations in phase I/II studies allow to select optimized vaccines for subsequent clinical efficacy testing in large scale phase III trials...
  4. ncbi Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring
    Daniel E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Immunother 27:298-308. 2004
    ..Comparable results were obtained with ELISPOT assays. In conclusion, this approach is well suited to assess T-cell responses as biologic endpoints in clinical vaccine studies...
  5. ncbi Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909
    Daniel E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Clin Invest 115:739-46. 2005
    ..In vitro, T cell clones recognized and killed melanoma cells in an antigen-specific manner. Thus, CpG 7909 is an efficient vaccine adjuvant that promotes strong antigen-specific CD8+ T cell responses in humans...
  6. ncbi In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells
    Daniel E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University Hospital CHUV, Lausanne, Switzerland
    Eur J Immunol 32:731-41. 2002
    ..Differentiation to protective CD8(+) effector cells may, however, require additional vaccine components that stimulate T cells more efficiently, a major challenge for the development of future immunotherapy...
  7. ncbi Toward improved immunocompetence of adoptively transferred CD8+ T cells
    Daniel E Speiser
    Ludwig Institute for Cancer Research, Division of Clinical Onco Immunology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Clin Invest 115:1467-9. 2005
    ....
  8. ncbi The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cells
    D E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Immunol 167:6165-70. 2001
    ..Thus, 2B4 expression correlates with CD8+ T cell differentiation in vivo...
  9. ncbi Can hTERT peptide (540-548) -specific CD8 T cells recognize and kill tumor cells?
    Daniel E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland
    Cancer Immun 2:14. 2002
    ..It would be highly useful if telomerase would emerge as a universal tumor antigen that can be targeted in the cancer immunotherapy of HLA-A2 positive patients...
  10. ncbi Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes
    Daniel E Speiser
    Ludwig Center for Cancer Research, University of Lausanne, Lausanne CH 1011, Switzerland
    Proc Natl Acad Sci U S A 108:15318-23. 2011
    ..In parallel, this was also found for EBV- and CMV-specific T cells. Thus, the nondominant clonotypes may contribute similarly to immunity as their dominant counterparts...
  11. ncbi Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen
    Daniel E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research and University of Lausanne, and Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, 1001 Lausanne, Switzerland
    Proc Natl Acad Sci U S A 105:3849-54. 2008
    ..Thus, novel vaccine formulations comprising potent immune stimulators may allow to circumvent the need for modified antigens and can induce highly functional T cells with precise antigen specificity...
  12. ncbi CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients
    D E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University Hospital, Lausanne, Switzerland
    Eur J Immunol 29:1990-9. 1999
    ..Preliminary results indicate that some tumor antigen-specific T cells may indeed be CD28- and express NK receptors in vivo...
  13. ncbi Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity
    Daniel E Speiser
    Clinical Investigation Center, Ludwig Institute for Cancer Research Ltd, Lausanne Branch, University of Lausanne, Switzerland
    Semin Immunol 22:144-54. 2010
    ..With carefully designed step-by-step modifications of innovative vaccine formulations, T cell vaccination can be optimized towards the goal of inducing therapeutic immune responses in humans...
  14. ncbi Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients
    Daniel E Speiser
    Clinical Tumor Immune Biology Unit, Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland
    J Immunother 33:848-58. 2010
    ..We conclude that vaccination with CpG loaded virus-like nanoparticles is associated with a human CD8 T-cell response with properties of a potential long-term immune protection from the disease...
  15. ncbi In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes
    D E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
    J Exp Med 190:775-82. 1999
    ..The lysis of melanoma cells by patient-derived CTLs was inhibited by the NK receptor CD94/NKG2A. Thus, tumor-specific CTL activity may be decreased through NK receptor triggering in vivo...
  16. ncbi New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site
    Victor Appay
    Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland
    J Immunol 177:1670-8. 2006
    ....
  17. ncbi Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine
    Danila Valmori
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University Hospital CHUV, 1011 Lausanne, Switzerland
    Cancer Immun 3:15. 2003
    ....
  18. ncbi A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination
    Daniel E Speiser
    Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital of Lausanne, Lausanne, Switzerland
    J Immunol 177:1338-48. 2006
    ..The observed successful boosting by peptide vaccination support further development of immunotherapy by including strategies to overcome immune escape...
  19. ncbi Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens
    Petra Baumgaertner
    Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne, Switzerland
    Cancer Res 66:1912-6. 2006
    ..Antigen-specific T-cells displayed an activated phenotype and secreted IFNgamma. The robust immune responses provide a solid basis for further development of human T-cell vaccination...
  20. ncbi In Vivo Persistence of Codominant Human CD8+ T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration
    Laurent Derre
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University Hospital of Lausanne, Lausanne, Switzerland
    J Immunol 179:2368-79. 2007
    ..Together, these data provide novel insight in long term in vivo persistence of T cell clonotypes associated with continued cell turnover but not replicative senescence or functional alteration...
  21. ncbi Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts
    Camilla Jandus
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research Ltd, Lausanne Branch, Hopital Orthopedique, Lausanne, Switzerland
    Cancer Res 69:8085-93. 2009
    ..This is the first report on direct ex vivo identification of antigen-specific FOXP3+ T cells by multimer labeling in cancer patients and on the direct assessment of the impact of peptide vaccination on immunoregulatory T cells...
  22. ncbi IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells
    Catherine Barbey
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois, Avenue Pierre Decker 4, CH 1005 Lausanne, Switzerland
    J Immunol 178:3566-74. 2007
    ..Because CD28 can mediate strong costimulatory signals, tight cytotoxicity control, as shown in this study through IL-12, may be particularly important for subsets of T cells expressing CD28...
  23. ncbi Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1
    Maha Ayyoub
    Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois, CH-1005 Lausanne, Switzerland
    Clin Cancer Res 9:669-77. 2003
    ..CONCLUSIONS: Patient immunization with the analog peptide leads to in vivo activation of T cells that were specific for the natural tumor antigen, demonstrating the usefulness of the analog peptide for melanoma immunotherapy...
  24. ncbi Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time
    Emanuela M Iancu
    Multidisciplinary Oncology Center, Lausanne, Switzerland
    J Immunol 183:319-31. 2009
    ..These findings reveal novel features of the highly sophisticated control of steady state protective T cell activity in healthy adults...
  25. ncbi Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma
    Victor Appay
    Multidisciplinary Oncology Center, University of Lausanne Hospitals CHUV, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Immunother 30:240-50. 2007
    ..Overall, these data provide further ground for the development of immunotherapeutic approaches to be both effective against melanoma and applicable in clinic...
  26. ncbi Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide
    Victor Appay
    Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland
    Eur J Immunol 36:1805-14. 2006
    ..Importantly, these cells are tumor-reactive...
  27. ncbi Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients
    Sebastien Wieckowski
    Division of Experimental Oncology, Multidisciplinary Oncology Center, Lausanne University Hospital, Lausanne, Switzerland
    J Immunol 183:5397-406. 2009
    ....
  28. ncbi Four functionally distinct populations of human effector-memory CD8+ T lymphocytes
    Pedro Romero
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research Lausanne Branch, University Hospital of Lausanne, Lausanne, Switzerland
    J Immunol 178:4112-9. 2007
    ..Finally, memory CD8+ T cells not only include central-memory cells but also EM(1) cells, which differ in CCR7 expression and may therefore confer memory functions in lymphoid and peripheral tissues, respectively...
  29. ncbi Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA
    Danielle Lienard
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Cancer Immun 4:4. 2004
    ..We conclude that repeated vaccination with Melan-A peptide in IFA frequently leads to sustained responses of specific CD8 T cells that are detectable ex vivo and correlate with inflammatory skin reactions...
  30. ncbi BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination
    Laurent Derre
    Ludwig Institute for Cancer Research, Hopital Orthopedique, Niveau 5 Est, Av Pierre Decker 4, Lausanne, Switzerland
    J Clin Invest 120:157-67. 2010
    ..Thus, BTLA activation inhibits the function of human CD8+ cancer-specific T cells, and appropriate immunotherapy may partially overcome this inhibition...
  31. ncbi Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers
    Gilles Bioley
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital, Lausanne, Switzerland
    J Immunol 177:6769-79. 2006
    ..Together, these results provide the basis for monitoring of naturally occurring and vaccine-induced Melan-A/MART-1-specific CD4 T cell responses, allowing precise and ex vivo characterization of responding T cells...
  32. ncbi Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues
    Laurent Derre
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, New York, NY, USA
    Proc Natl Acad Sci U S A 105:15010-5. 2008
    ..Finally, this in-depth study of recognition of a self-antigen suggests that in part similar biophysical mechanisms shape TCR repertoires toward foreign and self-antigens...
  33. ncbi Dextramers: new generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8+ T cells
    Pascal Batard
    Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital (CHUV, Switzerland
    J Immunol Methods 310:136-48. 2006
    ..Thus, these could become the reagents of choice as the antigen-specific T cell labeling transitions from basic research to clinical application...
  34. ncbi Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant
    Danielle Lienard
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Hopital Orthopedique, CH 1011 Lausanne, Switzerland
    J Immunother 32:875-83. 2009
    ..Antibody responses to P40 were observed in all patients. We conclude that vaccination with peptide and P40 was feasible and induced ex vivo detectable tumor antigen specific T cell responses in 6 of 14 patients with advanced melanoma...
  35. ncbi Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients
    Julien Laurent
    Multidisciplinary Oncology Center, University of Lausanne Hospitals, Ludwig Institute for Cancer Research Ltd, University of Lausanne, Switzerland
    J Immunother 33:723-34. 2010
    ..We conclude that short-term chemotherapy promoted homeostatic lymphocyte proliferation depending on the intensity of lymphocyte depletion, however without preferential expansion of tumor antigen-specific T cells...
  36. ncbi Novel soluble HLA-A2/MELAN-A complexes selectively stain a differentiation defective subpopulation of CD8+ T cells in patients with melanoma
    Philippe Guillaume
    Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland
    Int J Cancer 127:910-23. 2010
    ....
  37. ncbi Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma
    Gabriel Bricard
    Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne, Switzerland
    J Immunol 174:1709-16. 2005
    ....
  38. ncbi Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma
    Pedro Romero
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital CHUV, Lausanne, Switzerland
    Immunol Rev 188:81-96. 2002
    ....
  39. ncbi Thymic selection generates a large T cell pool recognizing a self-peptide in humans
    Alfred Zippelius
    Division of Clinical Onco Immunology, University Hospital CHUV, 1011 Lausanne, Switzerland
    J Exp Med 195:485-94. 2002
    ..This represents the only known naive self-peptide-specific T cell repertoire directly accessible in humans...
  40. ncbi Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose
    Tanja Lövgren
    Clinical Tumor Biology and Immunotherapy Unit, Ludwig Center of the University of Lausanne, Hôpital Orthopédique 05 1552, Av Pierre Decker 4, Lausanne, Switzerland
    Cancer Immunol Immunother 61:817-26. 2012
    ..We conclude that low peptide dose vaccination generated CD8+ T cell responses with stronger cytotoxicity and lower CD8 dependence...
  41. ncbi A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide
    Laurent Derre
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Lausanne, Switzerland
    J Immunol 179:7635-45. 2007
    ..We conclude that the two peptides should be regarded as distinct epitopes when analyzing tumor immunity and developing immunotherapy against melanoma...
  42. ncbi Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients
    Pedro M S Alves
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Hopital Orthopedique, HO 05, rue Pierre Decker, 4, 1005, Lausanne, Switzerland
    Cancer Immunol Immunother 56:1795-805. 2007
    ..However, the low avidity of the specific CTLs generated from cancer patients as well as the high-antigen expression levels required for CTL recognition pose serious concerns for the use of CEA694-702 in cancer immunotherapy...
  43. ncbi Dominant human CD8 T cell clonotypes persist simultaneously as memory and effector cells in memory phase
    Cedric Touvrey
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Lausanne, Switzerland
    J Immunol 182:6718-26. 2009
    ..Moreover, our sequencing analysis revealed, for the first time in humans, that identical clonotypes can coexist as both memory and effector T cells, thereby supporting the principle of multipotent clonotypic differentiation...
  44. ncbi Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors
    Frederique Anne Le Gal
    Laboratory of Tumor Immunology, Division of Oncology, Department of Internal Medicine, University Hospital, Geneva, Switzerland
    J Invest Dermatol 127:622-9. 2007
    ..Focusing research on patients with favorable outcomes may help to identify parameters that are crucial for an efficient antitumor response and to optimize cancer immunotherapy...
  45. ncbi Melan-A/MART-1-specific CD8 T cells: from thymus to tumor
    Mikael J Pittet
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University Hospital CHUV, 1011 Lausanne, Switzerland
    Trends Immunol 23:325-8. 2002
  46. ncbi Human thymus exports naive CD8 T cells that can home to nonlymphoid tissues
    Alfred Zippelius
    Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital, Lausanne, Switzerland
    J Immunol 172:2773-7. 2004
    ..Once seeded in the periphery, naive CCR7(+)CD62L(+) CD8 T cells patrol secondary lymphoid organs, whereas naive CCR7(-)CD62L(-) CD8 T cells selectively migrate to peripheral tissues such as skin...
  47. ncbi Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients
    Lukas Baitsch
    Clinical Tumor Immune Biology Unit, Ludwig Institute for Cancer Research, Lausanne, Switzerland
    J Clin Invest 121:2350-60. 2011
    ..Functional T cell impairment is mediated by inhibitory receptors and further molecular pathways, which represent potential targets for cancer therapy...
  48. ncbi Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples
    Victor Appay
    Immunology Group, Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland
    J Immunol Methods 309:192-9. 2006
    ..While the need to purify and cryopreserve PBMC for subsequent studies is obvious, the use of whole blood has the advantage of providing unbiased results and only small amounts of blood are used...
  49. ncbi Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity
    Sara Colombetti
    Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland
    J Immunol 176:6560-7. 2006
    ....
  50. ncbi Simultaneous coexpression of memory-related and effector-related genes by individual human CD8 T cells depends on antigen specificity and differentiation
    Bhawna Gupta
    Department of Research, Lausanne University Hospital, Lausanne, Switzerland
    J Immunother 35:488-501. 2012
    ..In summary, direct ex vivo high-resolution molecular characterization of individual T cells provides key insights into the processes shaping the functional properties of tumor-specific and virus-specific T cells...
  51. ncbi Therapeutic cancer vaccines based on molecularly defined human tumor antigens
    Pedro Romero
    Divison of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital, Avenue Pierre Decker 4, 1005 Lausanne, Switzerland
    Vaccine 20:A2-7. 2002
    ..Efficient therapeutic vaccination should aim at boosting naturally occurring anti-tumor responses and at sustaining a large contingent of tumor antigen-specific and fully functional effector T cells at tumor sites...
  52. ncbi Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex
    Mikael J Pittet
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University Hospital, Lausanne, Switzerland
    J Immunol 176:2330-6. 2006
    ..We show that these cells resemble their counterparts in HLA-A*0201-positive individuals, based on their structural and functional attributes...
  53. ncbi Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization
    Lukas Baitsch
    Clinical Tumor Biology and Immunotherapy Unit, Ludwig Center, University of Lausanne, Lausanne, Switzerland
    PLoS ONE 7:e30852. 2012
    ..Blocking multiple inhibitory receptors simultaneously or sequentially may improve T-cell based therapies, but further studies are necessary to clarify the role of each receptor-ligand pair...
  54. ncbi Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function
    Daphne A Schmid
    Multidisciplinary Oncology Center, Lausanne University Hospital, Switzerland
    J Immunol 184:4936-46. 2010
    ..We propose that rational design of improved self-specific TCRs may not need to be optimized beyond a given affinity threshold to achieve both optimal T cell function and avoidance of the unpredictable risk of cross-reactivity...
  55. ncbi Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination
    Emanuela M Iancu
    Department of Research, University Hospital Center CHUV and University of Lausanne UNIL, c o HO, Niv 5, Labo 1532, Avenue Pierre Decker 4, 1011 Lausanne, Switzerland
    J Biomed Biotechnol 2011:452606. 2011
    ..Together, the described approaches advance our knowledge of T-cell mediated-protection from human diseases...
  56. ncbi Quantitative multiparameter assays to measure the effect of adjuvants on human antigen-specific CD8 T-cell responses
    Laurent Derre
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Lausanne, Switzerland
    Methods Mol Biol 626:231-49. 2010
    ..In this regard, hundreds of clinical vaccination trials have been implemented during the last 15 years, and monitoring techniques become more and more standardized...
  57. ncbi Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination
    Pedro Romero
    Divison of Clinical Onco Immunology, Lausanne Branch, University Hospital CHUV, Ludwig Institute for Cancer Research, Lausanne, Switzerland
    Cancer Immunol Immunother 53:249-55. 2004
    ..Recent progress in our ability to quantitatively and qualitatively monitor tumor antigen specific CD8 T-cell responses will greatly help in making rapid progress in this field...
  58. ncbi An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain
    Verena Voelter
    Multidisciplinary Oncology Center, University of Lausanne Hospitals (CHUV, Lausanne, Switzerland
    Cancer Immun 8:6. 2008
  59. ncbi Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors
    Gabriel Bricard
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland
    J Immunol 182:5140-51. 2009
    ....
  60. ncbi Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells
    Petra Baumgaertner
    Clinical Tumor Immune Biology Unit, Ludwig Center for Cancer Research of the University of Lausanne, Switzerland
    Int J Cancer 130:2607-17. 2012
    ..We conclude that human tumor-specific CD8 T-cells can reach functional competence in vivo, encouraging further development and Phase III trials assessing the clinical efficacy of robust vaccination strategies...
  61. ncbi Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood
    Camilla Jandus
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital CHUV, Hôpital Orthopédique Niv 5, Aile Est, Av Pierre Decker 4, 1005, Lausanne, Switzerland
    Cancer Immunol Immunother 57:1795-805. 2008
    ..Together, our data suggest that local accumulation and differentiation of Tregs is, at least in part, tumor-driven, and illustrate a reliable combination of markers for their monitoring in various clinical settings...
  62. ncbi Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases
    M J Pittet
    Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital, Lausanne, Switzerland
    J Immunol 166:7634-40. 2001
    ..Thus, the high sensitivity of the assay provides a valuable tool to monitor effector T cell responses in different clinical situations...
  63. ncbi Assessing ageing of individual T lymphocytes: mission impossible?
    Emanuela M Iancu
    Division of Experimental Oncology, Multidisciplinary Oncology Center CePO, Avenue Pierre Decker 4, CH 1005 Lausanne, Switzerland
    Mech Ageing Dev 129:67-78. 2008
    ....
  64. ncbi Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide
    M J Pittet
    Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Clin Cancer Res 7:796s-803s. 2001
    ..Altogether, these results indicate that large numbers of functionally active tumor Ag-specific CD8+ T cells can be obtained and maintained at high levels after in vivo activation by repeated peptide-based vaccination...
  65. ncbi The human T cell response to melanoma antigens
    Pedro Romero
    Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital (CHUV, Lausanne, Switzerland
    Adv Immunol 92:187-224. 2006
    ..This chapter reviews recent knowledge on human CD8 and CD4 T cell responses to melanoma antigens...
  66. ncbi The CD4-like molecule LAG-3, biology and therapeutic applications
    Sophie Sierro
    Ludwig Institute for Cancer Research Ltd, Epalinges, Switzerland
    Expert Opin Ther Targets 15:91-101. 2011
    ..Recent clinical trials produced encouraging results, especially when the human dimeric soluble form of LAG-3 (hLAG-3-Ig) was used in combination with chemotherapy...
  67. ncbi Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells
    D E Speiser
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Eur J Immunol 31:459-66. 2001
    ..Thus, activated CD8(+) T cells specialize and exert distinct functions correlating with surface molecule expression...
  68. ncbi Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy
    M Montes
    Multidisciplinary Oncology Center (CePO, University Hospital (CHUV, Lausanne, Switzerland
    Clin Exp Immunol 142:292-302. 2005
    ..Our results provide an important basis for the rapid in vitro expansion of autologous T cells from the circulating lymphocyte pool using a simple procedure, which is necessary for the development of adoptive transfer therapies...
  69. ncbi Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing
    M Ayyoub
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University Hospital, Lausanne, Switzerland
    Eur J Immunol 31:2642-51. 2001
    ..Furthermore, in vitro proteasome digestion studies revealed inadequate hTERT processing. Altogether, these results raise questions on the use of hTERT(540) peptide for cancer immunotherapy...
  70. ncbi Neonatal tolerance to MIs-1a determinants: deletion or anergy of V beta 6+ T lymphocytes depending upon MHC compatibility of neonatally injected cells
    D E Speiser
    Laboratory for Experimental Pathology, Institute of Pathology, University Hospital, Zurich, Switzerland
    Int Immunol 3:127-34. 1991
    ..Taken together, our data indicate that neonatal tolerance to MIs-1a can be accomplished by either clonal deletion or clonal anergy, and that it does not necessarily correlate with tolerance to MHC determinants...
  71. ncbi Preferential positive selection of V alpha 2+ CD8+ T cells in mouse strains expressing both H-2k and T cell receptor V alpha a haplotypes: determination with a V alpha 2-specific monoclonal antibody
    H Pircher
    Institute of Pathology, University Hospital, Zurich, Switzerland
    Eur J Immunol 22:399-404. 1992
    ....
  72. ncbi Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients
    M J Pittet
    Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital, 1011 Lausanne, Switzerland
    Int Immunopharmacol 1:1235-47. 2001
    ....
  73. ncbi Tolerance to Mlsa by clonal deletion of V beta 6+ T cells in bone marrow and thymus chimeras
    D E Speiser
    Institute of Pathology, University Hospital, Zurich, Switzerland
    Thymus 13:27-33. 1989
    ..Preliminary results suggest that APCs presenting Mlsa during negative selection of V beta 6+ cells in the thymus are radiosensitive and derived from lymphohemopoietic stem cells...
  74. ncbi Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance
    Linh T Nguyen
    Departments of Immunology and Medical Biophysics, Ontario Cancer Institute, 610 University Ave, Toronto, Ontario M5G 2M9, Canada
    J Exp Med 195:423-35. 2002
    ..Thus, in this model, tumor growth promotes activation of high avidity tumor-specific T cells instead of tolerance. Therefore, the host remains responsive to T cell immunotherapy...
  75. ncbi RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses
    Michael Schmitt
    Department of Internal Medicine III, University of Ulm, Ulm, Germany
    Blood 111:1357-65. 2008
    ..This study is registered at http://ISRCTN.org as ISRCTN32763606 and is registered with EudraCT as 2005-001706-37...
  76. ncbi Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer
    Pedro M S Alves
    NCCR, Molecular Oncology, ISREC, Ch des Boveresses 155, 1066 Epalinges, Switzerland
    Cancer Immunol Immunother 56:839-47. 2007
    ..Finally, evidence of a naturally acquired CT antigen-specific CD8(+) T cell response could be demonstrated. These results show that the expression of CT antigens in a subset of CRC patients induces readily detectable T cell responses...
  77. ncbi Tumor cell recognition efficiency by T cells
    Daniel E Speiser
    PLoS Med 2:e77; author reply e95. 2005
  78. ncbi Identification of tumor-associated antigens by large-scale analysis of genes expressed in human colorectal cancer
    Pedro M S Alves
    National Center of Competence in Research, Molecular Oncology, ISREC, Ch des Boveresses 155, 1066 Epalinges, Switzerland
    Cancer Immun 8:11. 2008
    ..Our data suggest that this sequence should be considered as a target of immunological interventions against colorectal cancer...
  79. ncbi Efficient T cell repertoire selection in tetraparental chimeric mice independent of thymic epithelial MHC
    Marianne M Martinic
    Institute of Experimental Immunology, Department of Pathology, University Hospital Zurich, Schmelzbergstrasse 12, CH 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 100:1861-6. 2003
    ..Therefore, in contrast to earlier results with irradiation or thymus chimeras, these relatively undisturbed tetraparental mice reveal that the MHC of nonthymic epithelial cells efficiently selects a functional T cell repertoire...
  80. ncbi Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles
    Katrin Schwarz
    Cytos Biotechnology AG, , Switzerland
    Eur J Immunol 35:816-21. 2005
    ..Thus, the use of VLP may avoid the requirement for complicated heterologous prime-boost regimens, facilitating the development of effective T cell-based vaccines...
  81. ncbi Immunological techniques: ex vivo characterization of T cell-mediated immune responses in cancer
    Daniel E Speiser
    Curr Opin Immunol 17:419-22. 2005